Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure

Annals of Allergy, Asthma and Immunology

Volumn 93, Issue 5, 2004, Pages 431-438

  Perry, Tamara T ^a   Corren, Jonathan ^b   Philip, George ^c   Kim, Eric H ^c   Conover Walker, Mary Kay ^a   Malice, Marie Pierre ^c   Massaad, Rachid ^c   Dass, S Balachandra ^c   Reiss, Theodore F ^c   Wood, Robert A ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Allergy Research Foundation   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; MONTELUKAST; PLACEBO;

ADULT; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOWER RESPIRATORY TRACT; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SPIROMETRY; SYMPTOMATOLOGY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT;

EID: 8644222141     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61409-3     Document Type: Article

References (37)

1. Von Mutius E. The rising trends in asthma and allergic disease. Clin Exp Allergy. 1998;28:45-49.
2. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma: a population-based study of young adults. Am J Respir Crit Care Med. 2000;162:1391-1396.
3. Nathan RA, Meltzer EO, Seiner JC, Storms W. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol. 1997;99:S808-S814.
4. Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol. 1999;104:534-540.
5. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000;106(Suppl):S201- S205.
6. Naclerio RM. Allergic rhinitis. N Engl J Med. 1991;325:860-869.
7. Sampson AP, Pizzichini E, Bisgaard H. Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. J Allergy Clin Immunol. 2003;111:S49-S59.
8. Lam S, Chan H, LeRiche JC, Chan-Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol. 1988;81:711-717.
9. 4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol. 1988;82:414-418.
10. Liu MC, Hubbard WC, Proud D, et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics: cellular, mediator, and permeability changes. Am Rev Respir Dis. 1991;144:51-58.
11. Creticos PS, Peters SP, Adkinson NF Jr, et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med. 1984;310:1626-1630.
12. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158:1213-1220.
13. Reiss TF, Knorr B, Malmstrom K, et al. Clinical efficacy of montelukast in adults and children. Clin Exp Allergy Rev. 2001;1:264-273.
14. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med. 2003;167:528-533.
15. Diamant Z, Grootendorst DC, Veselic-Charvat M, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy. 1999;29:42-51.
16. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105:917-922.
17. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF; Montelukast Fall Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88:592-600.
18. Philip G, Malmstrom K, Hampel FC Jr, et al; Montelukast Spring Rhinitis Study Group. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020-1028.
19. van Adelsberg J, LaForce CF, Weinstein SF, et al. Randomized controlled trial evaluating clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90:214-222.
20. van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003;58:1268-1276.
21. Chapman MD, Wood RA. The role and remediation of animal allergens in allergic diseases. J Allergy Clin Immunol. 2001;107:S414-S421.
22. Wood RA, Eggleston PA. The effects of intranasal steroids on nasal and pulmonary responses to cat exposure. Am J Respir Crit Care Med. 1995;151:315-320.
23. Corren J, Spector S, Fuller L, Minkwitz M, Mezzanotte W. Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. Ann Allergy Asthma Immunol. 2001;87:211-217.
24. Phipatanakul W, Eggleston PA, Conover-Walker MK, Kesavanathan J, Sweitzer D, Wood RA. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge. J Allergy Clin Immunol. 2000;105:704-710.
25. Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA, et al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol. 2002;109:794-799.
26. Wood RA, Laheri AN, Eggleston PA. The aerodynamic characteristics of cat allergen. Clin Exp Allergy. 1993;23:733-739.
27. Chapman MD, Aalberse RC, Brown MJ, Platts-Mills TA. Monoclonal antibodies to the major feline allergen Fel d I: single-step affinity purification of Fel d I, N-terminal sequence analysis, and development of a 2-site immunoassay to assess Fel d I exposure. J Immunol. 1988;140:812-818.
28. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84:1065-1073.
29. Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003;111:1171-1183.
30. Canonica GW. Evaluation and management of patients with asthma and allergic rhinitis: exploring the potential role for leukotriene receptor antagonists. Clin Exp Allergy Rev. 2003;3:61-62.
31. Bousquet J, Van Cauwenberge P, Khaltaev N; ARIA Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147-S334.
32. Dahlen SE. Cysteinyl leukotrienes as common mediators of asthma and allergic rhinitis. Clin Exp Allergy Rev. 2003;3:69-73.
33. Pawankar R. Exploring the role of leukotriene receptor antagonists in the management of allergic rhinitis and comorbid asthma. Clin Exp Allergy Rev. 2003;3:74-80.
34. Atherton HA, White PT, Hewett G, Howells K. Relationship of daytime asthma symptom frequency to morning peak expiratory flow. Eur Respir J. 1996;9:232-236.
35. Shingo S, Zhang J, Reiss TF. Correlation of airway obstruction and patient-reported endpoints in clinical studies. Eur Respir J. 2001;17:220-224.
36. Zhang J, Yu C, Holgate ST, Reiss TF. Variability and lack of predictive ability of asthma end-points in clinical trials. Eur Respir J. 2002;20:1102-1109.
37. Bollinger MB, Eggleston PA, Johnson EF, Wood RA. Cat antigen in homes with and without cats may induce allergic symptoms. J Allergy Clin Immunol. 1996;97:907-914.